Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis

Daniel Escorsim Machado, Jamila Alessandra Perini, Margarida Maria Camoes Orlando, Margarida Maria Camões Orlando, Ralph Santos-Oliveira, Ralph Santos‐Oliveira
BioMed research international · 2015 · vol. 2015 , pp. 1–4 · doi:10.1155/2015/751460 · PMID:26240826 · W1502163996
article OA: hybrid CC0 ⤵ 5 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Bevacizumab-99mTc noninvasively imaged induced endometriosis lesions in rats, demonstrating potential for gynecological nuclear medicine applications with hepatobiliary excretion and a significantly lower administered dose.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use for Nuclear Medicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion. It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Bevacizumab Endometriosis Endometriosis Radionuclide Imaging Technetium Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Animals Bevacizumab Endometriosis Female Isotope Labeling Isotope Labeling Metabolic Clearance Rate Organ Specificity Radionuclide Imaging Radiopharmaceuticals Radiopharmaceuticals Radiopharmaceuticals

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:46.044120+00:00
License: CC0 · commercial use OK